의료용 멤브레인 시장(-2030년) : 재료, 프로세스 기술, 용도, 지역별

The medical membranes market is projected to reach USD 6.66 billion by 2030 from USD 4.31 billion in 2025, at a CAGR of 9.1% during the forecast period. The global medical membranes market is driven by the increasing number of chronic kidney disease and diabetes patients. Continuous innovations in membrane technology like better biocompatibility, antifouling coatings, and nanofiltration capabilities are making drug purification, bioprocessing, and artificial organ applications possible.

Additionally, the increasing number of surgical procedures, preference for advanced wound dressings, and tissue engineering scaffolds are also supporting market growth. Meanwhile, there is strong investment in single-use disposable membrane systems in biotech and pharmaceutical manufacturing for eliminating cross-contamination. Moreover, the healthcare infrastructure in emerging markets (especially Asia Pacific), the aging population in mature regions, and significant R&D on bio-artificial organs and regenerative medicine are all contributing to the market growth.

"Polyvinylidene fluoride (PVDF) is the fastest-growing material segment in the medical membranes market during the forecast period."

Polyvinylidene fluoride (PVDF) is the fastest-growing segment in the medical membranes market due to its excellent properties. PVDF is known for its chemical resistance, heat stability, physical strength, and low protein adherence and, thus, is widely used in the purification of liquids in pharmaceuticals and biopharmaceuticals, alongside blood filtering, drug purification, and filtration of the final products of biopharmaceuticals. Hydrophilic PVDF membranes are increasingly used in medical diagnostics and biologics production, driven by the worldwide rise in chronic diseases, the growing focus on personalized medicine, and the expanding aging population. PVDF's biocompatibility is a key factor for innovations in tissue engineering, wound dressings, and virus removal, which makes it superior to competitors such as PTFE or PESU. At the same time, the pandemic-induced surge in pharmaceutical manufacturing and increased investments in advanced filtration technologies also favor PVDF.

"Ultrafiltration is projected to be the largest process technology segment in the medical membranes market during the forecast period."

Ultrafiltration (UF) is the largest technology segment in the overall medical membranes market due to its essential application in hemodialysis. Hemodialysis overcomes the limits of kidney function in more than 3 million end-stage renal disease patients, curing them by highly efficient removal of ureotoxins and keeping essential proteins in the body. UF membranes are often made from polysulfone, polyethersulfone, or modified PES, and they have precise corresponding molecular weight cut-offs (5-50kDa) that give excellent biocompatibility as well as high flux rates and superior hemocompatibility. Thus, they have become the standard for purification in dialysis clinics and ICUs. The strong growth of the medical membranes market is also supported by the expanding use of ultrafiltration (UF) beyond renal therapy. UF is widely applied in microbiology and pharmaceutical downstream processing for concentrating, diafiltering, and exchanging buffers in monoclonal antibodies, vaccines, and recombinant proteins, all of which are increasing rapidly with the rise of biologics. Its ability to pump at low transmembrane pressure and usage of advanced surface modifications to reduce fouling make it even more preferred over microfiltration, reverse osmosis, or nanofiltration in high-volume, high-value medical applications.

"Europe is projected to be the second-largest medical membranes market during the forecast period."

Europe is the second-largest medical membranes market. The market in the region is driven by its excellent healthcare systems, high spending on renal care per capita, and a large number of elderly people with a high prevalence of chronic kidney diseases. The market in the region is also supported by the presence of major membrane manufacturers with significant R&D and production capacity in Germany, France, Italy, and Switzerland. Stringent EU regulatory standards ensure that only the best products are delivered to the market. However, this creates barriers for new players. Moreover, widespread reimbursement for dialysis treatments, the growing use of single-use bioprocessing systems in the fast-expanding biologics sector, and significant public and private investments in fields like regenerative medicine and bioartificial organs contribute to the demand for the product.

Extensive primary interviews were conducted to determine and verify the market size for several segments and subsegments and the information gathered through secondary research.

The breakdown of primary interviews is given below:

• By Department: Tier 1 - 40%, Tier 2 - 25%, and Tier 3 - 35%
• By Designation: C Level - 35%, Director Level - 30%, and Executives - 35%
• By Region: North America - 25%, Europe - 45%, Asia Pacific - 20%, South America - 5%, and Middle East & Africa - 5%

Asahi Kasei Corporation (Japan), Mann+Hummel (Germany), Sartorius AG (Germany), Merck KGaA (Germany), Solventum (US), Cytiva (US), W. L. Gore & Associates, Inc. (US), Kovalus Separation Solutions (US),and Cobetter (China), among others, are some of the key players in the medical membranes market. The study includes an in-depth competitive analysis of these key players in the medical membranes market, with their company profiles, recent developments, and key market strategies.

Research Coverage

The market study covers the medical membranes market across various segments. It aims to estimate the market size and the growth potential of this market across different segments based on material, process technology, application, and region. The study also includes an in-depth competitive analysis of key players in the market, their company profiles, key observations related to their products and business offerings, recent developments undertaken by them, and key growth strategies adopted by them to improve their position in the medical membranes market.

Key Benefits of Buying the Report

The report is expected to help the market leaders/new entrants in this market with the closest approximations of the revenue numbers of the overall medical membranes market and its segments and subsegments. This report is projected to help stakeholders understand the competitive landscape of the market, gain insights to improve the position of their businesses, and plan suitable go-to-market strategies. The report also aims to help stakeholders understand the pulse of the market and provide them with information on the key market drivers, restraints, challenges, and opportunities.

The report provides insights into the following pointers:

• Analysis of key drivers (Rising prevalence of chronic diseases, Growing adoption of membrane-based separation technologies, Increasing number of surgical procedures), restraints (High cost of advanced medical membranes, Stringent regulatory approval processes, Risk of membrane fouling and limited lifespan of membranes), opportunities (Growing demand for single-use membrane systems in bioprocessing, Expansion in emerging markets, Integration of nanotechnology and smart membranes), challenges (Complexity in scaling up production of high-performance membranes, Environmental concerns, and Intense competition).
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the medical membranes market
• Market Development: Comprehensive information about lucrative markets - the report analyses the medical membranes market across varied regions.

Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the medical membranes market

• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Asahi Kasei Corporation (Japan), Mann+Hummel (Germany), Sartorius AG (Germany), Merck KGaA (Germany), Solventum (US), Cytiva (US), W. L. Gore & Associates, Inc. (US), Kovalus Separation Solutions (US), and Cobetter (China), among others

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
  • 1.3.5 UNIT CONSIDERED
• 1.4 STAKEHOLDERS

2 EXECUTIVE SUMMARY

3 PREMIUM INSIGHTS

• 3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN MEDICAL MEMBRANES MARKET
• 3.2 MEDICAL MEMBRANES MARKET, BY APPLICATION
• 3.3 MEDICAL MEMBRANES MARKET, BY MATERIAL
• 3.4 MEDICAL MEMBRANES MARKET, BY PROCESS TECHNOLOGY
• 3.5 MEDICAL MEMBRANES MARKET, BY REGION

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Rising prevalence of chronic diseases
    • 4.2.1.2 Advancements in biotechnology and drug delivery systems
    • 4.2.1.3 Rising demand for hemodialysis and filtration technologies
    • 4.2.1.4 Expansion of healthcare infrastructure and increasing access globally
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High manufacturing and production costs
    • 4.2.2.2 Stringent regulatory approvals and compliance
    • 4.2.2.3 Membrane fouling and degradation issues
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Growing demand for single-use membrane systems in bioprocessing
    • 4.2.3.2 Rapid expansion of medical membranes into emerging economies
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Complexity in scaling up production of high-performance membranes
    • 4.2.4.2 Environmental concerns
• 4.3 UNMET NEEDS AND WHITE SPACES
  • 4.3.1 UNMET NEEDS IN MEDICAL MEMBRANES MARKET
  • 4.3.2 WHITE SPACE OPPORTUNITIES
• 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
  • 4.4.1 INTERCONNECTED MARKETS
  • 4.4.2 CROSS-SECTOR OPPORTUNITIES
• 4.5 EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFTS
  • 4.5.1 EMERGING BUSINESS MODELS
  • 4.5.2 ECOSYSTEM SHIFTS
• 4.6 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
  • 4.6.1 KEY MOVES AND STRATEGIC FOCUS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF SUPPLIERS
  • 5.1.4 BARGAINING POWER OF BUYERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC INDICATORS
  • 5.2.1 GLOBAL GDP TRENDS
• 5.3 VALUE CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND, BY REGION
• 5.6 TRADE ANALYSIS
  • 5.6.1 IMPORT SCENARIO (HS CODE 901890)
  • 5.6.2 EXPORT SCENARIO (HS CODE 901890)
• 5.7 KEY CONFERENCES AND EVENTS
• 5.8 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.9 INVESTMENT AND FUNDING SCENARIO
• 5.10 CASE STUDY ANALYSIS
  • 5.10.1 ENSURING RELIABLE CLEANABILITY OF MEDICAL ULTRAFILTRATION MEMBRANES - MERCK MILLIPORE
  • 5.10.2 ADVANCED MEDICAL MEMBRANE SOLUTION FOR HOSPITAL WASTEWATER TREATMENT BY IMEMFLO
• 5.11 2025 US TARIFF
  • 5.11.1 INTRODUCTION
  • 5.11.2 KEY TARIFF RATES
  • 5.11.3 PRICE IMPACT ANALYSIS
  • 5.11.4 IMPACT ON KEY REGIONS
    • 5.11.4.1 North America
    • 5.11.4.2 Europe
    • 5.11.4.3 Asia Pacific
  • 5.11.5 IMPACT ON END-USE INDUSTRIES

6 STRATEGIC DISRUPTION THROUGH TECHNOLOGY, PATENTS, DIGITAL, AND AI ADOPTIONS

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 CELL MEMBRANE-COATED NANOPARTICLES (CNPS)
  • 6.1.2 BIOCOMPATIBLE AND BIODEGRADABLE COMPOSITE MEMBRANES
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 SURFACE MODIFICATION & ANTIMICROBIAL/ANTIFOULING COATINGS
• 6.3 TECHNOLOGY/PRODUCT ROADMAP
  • 6.3.1 SHORT-TERM (2025-2027) | FOUNDATION & EARLY COMMERCIALIZATION
  • 6.3.2 MID-TERM (2027-2030) | EXPANSION & STANDARDIZATION
  • 6.3.3 LONG-TERM (2030-2035+) | MASS COMMERCIALIZATION & DISRUPTION
• 6.4 PATENT ANALYSIS
  • 6.4.1 INTRODUCTION
  • 6.4.2 METHODOLOGY
  • 6.4.3 DOCUMENT TYPE
  • 6.4.4 INSIGHTS
  • 6.4.5 LEGAL STATUS OF PATENTS
  • 6.4.6 JURISDICTION ANALYSIS
  • 6.4.7 TOP APPLICANTS
  • 6.4.8 TOP 10 PATENT OWNERS IN LAST 10 YEARS
• 6.5 FUTURE APPLICATIONS
  • 6.5.1 NEXT-GENERATION HEMODIALYSIS & ARTIFICIAL ORGANS
  • 6.5.2 ADVANCED WOUND-CARE & TISSUE-ENGINEERING MEMBRANES
  • 6.5.3 CONTROLLED DRUG-DELIVERY & IMPLANTABLE THERAPEUTIC MEMBRANES
  • 6.5.4 POINT-OF-CARE DIAGNOSTICS & MICROFLUIDIC LAB-ON-CHIP DEVICES
  • 6.5.5 WEARABLE HEALTH SENSORS & CONTINUOUS BIOMARKER MONITORING
• 6.6 IMPACT OF AI/GEN AI ON MEDICAL MEMBRANES MARKET
  • 6.6.1 TOP USE CASES AND MARKET POTENTIAL
  • 6.6.2 BEST PRACTICES IN MEDICAL MEMBRANES PROCESSING
  • 6.6.3 CASE STUDIES OF AI IMPLEMENTATION IN MEDICAL MEMBRANES MARKET
  • 6.6.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
  • 6.6.5 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN MEDICAL MEMBRANES MARKET
• 6.7 SUCCESS STORIES AND REAL-WORLD APPLICATIONS
  • 6.7.1 PALL CORPORATION: HEMODIALYSIS MEMBRANES
  • 6.7.2 MERCK KGAA: BIOFUNCTIONAL MEMBRANES
  • 6.7.3 BAXTER INTERNATIONAL: EXTRACORPOREAL MEMBRANES

7 SUSTAINABILITY AND REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY INITIATIVES
• 7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES
• 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 BUYING CRITERIA
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS IN VARIOUS APPLICATIONS
• 8.5 MARKET PROFITABILITY
  • 8.5.1 REVENUE POTENTIAL
  • 8.5.2 COST DYNAMICS
  • 8.5.3 MARGIN OPPORTUNITIES IN KEY END-USE INDUSTRIES

9 MEDICAL MEMBRANES MARKET, BY MATERIAL

• 9.1 INTRODUCTION
• 9.2 POLYSULFONE (PSU) & POLYETHERSULFONE (PESU)
  • 9.2.1 ADVANCING DIALYSIS AND CLINICAL FILTRATION WITH BIOCOMPATIBLE, HIGH-FLUX MEMBRANE TECHNOLOGIES TO DRIVE MARKET
• 9.3 POLYVINYLIDENE FLUORIDE (PVDF)
  • 9.3.1 EXCELLENT MECHANICAL STRENGTH, THERMAL STABILITY, AND CHEMICAL RESISTANCE TO DRIVE MARKET
  • 9.3.2 HYDROPHOBIC PVDF MEMBRANE
  • 9.3.3 HYDROPHOBIC PVDF MEMBRANE
• 9.4 POLYTETRAFLUOROETHYLENE (PTFE)
  • 9.4.1 ADVANCING MEDICAL VENT FILTRATION WITH ULTRA-RESILIENT MEMBRANE MATERIALS TO DRIVE MARKET
• 9.5 POLYPROPYLENE (PP)
  • 9.5.1 OPTIMIZING THERMAL STABILITY FOR HIGH-TEMPERATURE USE TO DRIVE MARKET
• 9.6 POLYACRYLONITRILE (PAN)
  • 9.6.1 PROVIDES SUPERIOR CHEMICAL RESISTANCE IN AGGRESSIVE DRUG FILTRATION TO DRIVE MARKET
• 9.7 POLYAMIDE (PA)
  • 9.7.1 ENABLES HIGH PERMSELECTIVITY IN PHARMACEUTICAL NANOFILTRATION AND DRUG CONCENTRATION TO DRIVE MARKET
• 9.8 MODIFIED ACRYLICS
  • 9.8.1 DELIVERS UNMATCHED OPTICAL CLARITY FOR HIGH-SENSITIVITY DIAGNOSTIC DEVICES TO DRIVE MARKET
• 9.9 OTHER MATERIALS

10 MEDICAL MEMBRANES MARKET, BY PROCESS TECHNOLOGY

• 10.1 INTRODUCTION
• 10.2 ULTRAFILTRATION
  • 10.2.1 TRANSFORMING MEDICAL PURIFICATION WORKFLOWS WITH HIGH-PERFORMANCE MEMBRANE SOLUTIONS TO DRIVE MARKET
• 10.3 NANOFILTRATION
  • 10.3.1 REMOVES ENDOTOXINS, HORMONE RESIDUES, ANTIBIOTICS, AND OTHER TRACES FROM PROCESS WATER AND MEDICAL SOLUTIONS TO DRIVE MARKET
• 10.4 MICROFILTRATION
  • 10.4.1 RISING DEMAND FOR ENERGY-EFFICIENT AIR CONDITIONING SYSTEMS AND RETROFITTING OF OLDER BUILDINGS TO DRIVE MARKET
• 10.5 OTHER PROCESS TECHNOLOGIES

11 MEDICAL MEMBRANES MARKET, BY APPLICATION

• 11.1 INTRODUCTION
• 11.2 PHARMACEUTICAL FILTRATION
  • 11.2.1 ENHANCING BIOPHARMACEUTICAL SAFETY WITH HIGH-PERFORMANCE MEMBRANE SOLUTIONS TO DRIVE MARKET
• 11.3 HEMODIALYSIS
  • 11.3.1 EMPOWERING RENAL SUPPORT WITH PRECISION FILTRATION TO DRIVE MARKET
• 11.4 DRUG DELIVERY
  • 11.4.1 ENHANCING TREATMENT RELIABILITY THROUGH CONTROLLED DIFFUSION TECHNOLOGY TO DRIVE MARKET
• 11.5 IV FUSION & STERILE FILTRATION
  • 11.5.1 ADVANCING CLINICAL OUTCOMES THROUGH CUTTING-EDGE FILTRATION AND DELIVERY TO DRIVE MARKET
• 11.6 MEMBRANE OXYGENATOR
  • 11.6.1 DRIVING EFFICIENT AND SAFE OXYGEN DELIVERY WITH MEMBRANE INNOVATION TO DRIVE MARKET
• 11.7 APHERESIS MEMBRANE
  • 11.7.1 TRANSFORMING BLOOD TREATMENT THROUGH ADVANCED MEMBRANE TECHNOLOGY TO DRIVE MARKET
• 11.8 OTHER APPLICATIONS

12 MEDICAL MEMBRANES MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 ASIA PACIFIC
  • 12.2.1 CHINA
    • 12.2.1.1 Accelerating expansion in healthcare filtration technologies to drive market
  • 12.2.2 INDIA
    • 12.2.2.1 Seizing opportunities in cost-effective dialysis and filtration to drive market
  • 12.2.3 JAPAN
    • 12.2.3.1 Strengthening healthcare outcomes with high-tech filtration to drive market
  • 12.2.4 SOUTH KOREA
    • 12.2.4.1 Rising demand from healthcare, pharmaceutical, and biotechnology sector to drive market
  • 12.2.5 REST OF ASIA PACIFIC
• 12.3 NORTH AMERICA
  • 12.3.1 US
    • 12.3.1.1 Surge in construction activities to drive market
  • 12.3.2 CANADA
    • 12.3.2.1 Rise of new housing projects to drive market
  • 12.3.3 MEXICO
    • 12.3.3.1 Expanding industrial capabilities and healthcare systems to drive market
• 12.4 EUROPE
  • 12.4.1 GERMANY
    • 12.4.1.1 Surge in construction of residential infrastructure to drive market
  • 12.4.2 UK
    • 12.4.2.1 Rising demand for hemodialysis, pharmaceutical filtration, and IV infusion systems to drive market
  • 12.4.3 FRANCE
    • 12.4.3.1 Policy and financial incentives for building renovation and low-carbon heating to drive market
  • 12.4.4 ITALY
    • 12.4.4.1 Investments in residential buildings and renovation activities to drive market
  • 12.4.5 SPAIN
    • 12.4.5.1 High demand for commercial air conditioning units to drive market
  • 12.4.6 REST OF EUROPE
• 12.5 MIDDLE EAST & AFRICA
  • 12.5.1 SAUDI ARABIA
    • 12.5.1.1 Trend of small and affordable housing units to drive market
  • 12.5.2 UAE
    • 12.5.2.1 Projects aimed at promoting economic development to drive market
  • 12.5.3 SOUTH AFRICA
    • 12.5.3.1 Regional copper trade expansion to drive market
  • 12.5.4 REST OF MIDDLE EAST & AFRICA
• 12.6 SOUTH AMERICA
  • 12.6.1 BRAZIL
    • 12.6.1.1 Rapid industrial growth to drive market
  • 12.6.2 ARGENTINA
    • 12.6.2.1 Economic stabilization to drive market
  • 12.6.3 REST OF SOUTH AMERICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023-2025
• 13.3 REVENUE ANALYSIS, 2022-2024
• 13.4 MARKET SHARE ANALYSIS, 2024
• 13.5 COMPANY VALUATION AND FINANCIAL METRICS
• 13.6 PRODUCT COMPARISON
• 13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 13.7.1 STARS
  • 13.7.2 EMERGING LEADERS
  • 13.7.3 PERVASIVE PLAYERS
  • 13.7.4 PARTICIPANTS
  • 13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 13.7.5.1 Company footprint
    • 13.7.5.2 Region footprint
    • 13.7.5.3 Material footprint
    • 13.7.5.4 Process technology footprint
    • 13.7.5.5 Application footprint
• 13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 13.8.1 PROGRESSIVE COMPANIES
  • 13.8.2 RESPONSIVE COMPANIES
  • 13.8.3 DYNAMIC COMPANIES
  • 13.8.4 STARTING BLOCKS
  • 13.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 13.8.5.1 Detailed list of key startups/SMEs
    • 13.8.5.2 Competitive benchmarking of startups/SMEs
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 DEALS
  • 13.9.2 EXPANSIONS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 ASAHI KASEI CORPORATION
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 MnM view
      • 14.1.1.3.1 Right to win
      • 14.1.1.3.2 Strategic choices
      • 14.1.1.3.3 Weaknesses and competitive threats
  • 14.1.2 MANN+HUMMEL
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 MnM view
      • 14.1.2.3.1 Right to win
      • 14.1.2.3.2 Strategic choices
      • 14.1.2.3.3 Weaknesses and competitive threats
  • 14.1.3 SARTORIUS AG
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 MnM view
      • 14.1.3.3.1 Right to win
      • 14.1.3.3.2 Strategic choices
      • 14.1.3.3.3 Weaknesses and competitive threats
  • 14.1.4 MERCK KGAA
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Expansions
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Right to win
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses and competitive threats
  • 14.1.5 SOLVENTUM
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Deals
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Right to win
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses and competitive threats
  • 14.1.6 CYTIVA (DANAHER CORPORATION)
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Deals
      • 14.1.6.3.2 Expansions
    • 14.1.6.4 MnM view
  • 14.1.7 W. L. GORE & ASSOCIATES, INC.
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
    • 14.1.7.3 MnM view
  • 14.1.8 KOVALUS SEPARATION SOLUTIONS
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 MnM view
  • 14.1.9 COBETTER
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products offered
    • 14.1.9.3 MnM view
  • 14.1.10 POREX
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products offered
    • 14.1.10.3 MnM view
• 14.2 OTHER PLAYERS
  • 14.2.1 ADVANCED MICRODEVICES PVT. LTD.
  • 14.2.2 AMERICAN MEMBRANE CORPORATION
  • 14.2.3 AMS MEMTECH TECHNOLOGY (ZHEJIANG) CO., LTD
  • 14.2.4 APPLIED MEMBRANE TECHNOLOGY, INC.
  • 14.2.5 GRAVER TECHNOLOGIES
  • 14.2.6 MEDICA SPA
  • 14.2.7 MEMBRANE SOLUTIONS (NANTONG)
  • 14.2.8 NX FILTRATION
  • 14.2.9 OSMOTECH
  • 14.2.10 PERMIONICS GROUP
  • 14.2.11 REPLIGEN CORPORATION
  • 14.2.12 SYNDER FILTRATION, INC.
  • 14.2.13 THEWAY MEMBRANES
  • 14.2.14 UNISOL MEMBRANE TECHNOLOGY
  • 14.2.15 XINNA

15 RESEARCH METHODOLOGY

• 15.1 RESEARCH DATA
  • 15.1.1 SECONDARY DATA
    • 15.1.1.1 List of secondary sources
    • 15.1.1.2 Key data from secondary sources
  • 15.1.2 PRIMARY DATA
    • 15.1.2.1 List of primary interview participants-demand and supply side
    • 15.1.2.2 Key data from primary sources
    • 15.1.2.3 Breakdown of primary interviews
    • 15.1.2.4 Insights from industry experts
• 15.2 MARKET SIZE ESTIMATION
  • 15.2.1 BOTTOM-UP APPROACH
  • 15.2.2 TOP-DOWN APPROACH
• 15.3 FORECAST NUMBER CALCULATION
• 15.4 DATA TRIANGULATION
• 15.5 FACTOR ANALYSIS
• 15.6 RESEARCH ASSUMPTIONS
• 15.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 CUSTOMIZATION OPTIONS
• 16.4 RELATED REPORTS
• 16.5 AUTHOR DETAILS